Fig. 1.
Survival curves for the 30 patients receiving α-IFN plus cis-platinum and the 26 patients receiving no antitumor therapy.
Survival curves for the 30 patients receiving α-IFN plus cis-platinum and the 26 patients receiving no antitumor therapy.